- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04166006
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers. (RaC-Ad)
A Phase II Study on Adjuvant Vaccination With Dendritic Cells Loaded With Autologous Tumor Homogenate in Resected Stage IV Rare Cancers: Head&Neck (H&N), Neuroendocrine Tumors (NET) and Soft Tissue Sarcoma (STS).
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Oriana Nanni, DR
- Phone Number: +390543739266
- Email: oriana.nanni@irst.emr.it
Study Locations
-
-
FC
-
Meldola, FC, Italy, 47014
- Recruiting
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
-
Contact:
- Laura Ridolfi, MD
- Phone Number: +390543739274
- Email: laura.ridolfi@irst.emr.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have histologically confirmed stage IV Head&Neck Squamous Cell Carcinoma (HNSCC), NeuroEndocrine Tumors (NET) or Soft Tissue Sarcoma (STS) surgically treated with radical intent.
- The autologous surgical specimen must have been collected and sent to the Somatic Cell Therapy Lab and must fulfil all the acceptance criteria prescribed by the Good Manufactory Practice (GMP) procedures.
- The patient must be disease-free, as assessed by CT scan or MRI of the chest, abdomen, pelvis performed within 60 days before enrolment. If the resected lesions occurred in other sites, these must be also included in the baseline CT scan and in all the subsequent evaluations.
- Patients disease-free candidates for only observation as per clinical practice (no standard treatment is available after surgery)
- The patient must have recovered from all the adverse events related to previous surgery.
- Age ≥18 years.
- Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1.
Patient must have acceptable organ function, defined as:
- Haemoglobin >10 g/dl
- White blood cells ≥3000/μl.
- Absolute neutrophil count ≥1500/μl.
- Platelets≥75000/μl.
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 times the upper institutional reference level.
- Total bilirubin <1.5 times the upper institutional reference level.
- Serum creatinine <1.5 times the upper institutional reference level.
- Patients aged 70 years or older must have left ventricular ejection fraction not lower than 55% as assessed by echocardiography.
- Female patients of childbearing potential and all male patients must accept and be compliant with an highly effective contraceptive method (i.e. with a failure rate of <1% per year: double barrier method, one barrier method plus spermicidal, intrauterine device, or oral contraception) from informed consent signature and up to three months after end of study. For this purpose are considered of childbearing potential all female subjects after puberty unless they are post-menopausal for at least two years or are surgically sterile. Complete abstinence from sexual intercourses is acceptable if patients' lifestyle guarantees his/her strict compliance with this prescription in the judgement of the Investigator.
- The patient is willing and able to give written informed consent for the study.
Exclusion Criteria:
- Patients with residual disease after surgery. Marginal resection of any lesion in the absence of clinically evident residual disease is acceptable.
- Patient who completed surgery more than 90 days before study enrolment.
- History of other neoplastic diseases in the previous 5 years, except basal cell carcinoma of the skin and in situ carcinoma of the cervix uteri treated with curative surgery.
- History of congenital or acquired immunodeficiency, including history of organ transplantation.
Any positivity for the serologic markers of hepatitis B virus (HBV) (including at least anti- Hepatitis B surface antibodies (HBs) and hepatitis B core (HBc) antibodies, hepatitis C virus (HCV), HIV or Treponema pallidum. The serologic tests must have been performed within 30 days before any GMP-regulated activity (i.e. surgical resection and leukapheresis). The sole positivity for antibodies against the HBV surface antigen (i.e.
with all other HBV markers negative) is indicative of previous HBV vaccination and therefore is acceptable.
- Female patients who are pregnant or nursing.
- Participation in another clinical trial with any investigational agent within 30 days prior to study screening.
- Any active inflammatory or autoimmune disease requiring systemic steroids or other immunomodulatory agents as detailed in section 6.4, or potentially requiring such treatments during the study treatment in the judgement of the Investigator.
- Any clinical condition that, in the opinion of the Investigator or the Transfusion Medicine specialist, is a contraindication to leukapheresis. In addition, all patients aged 70 or older must be evaluated by a cardiology specialist before the procedure to exclude any clinically relevant cardiac condition and any grade 3-4 cardiac arrhythmia, even if asymptomatic.
- Any uncontrolled serious intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations potentially impacting patient safety and compliance in the opinion of the Investigator.
- Refusal of giving written informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1), followed by Interleukin (IL) - 2 (IL-2), at a dose of 3 Million Units (MU), given by subcutaneous injection daily for five days (days 3-7). This constitutes a treatment cycle. Treatment cycles are repeated every 28 days up to a maximum of six cycles. |
7-14×106 autologous dendritic cells loaded with autologous tumour homogenate given by intradermal injection (day 1)
Autologous DC vaccine is followed by IL-2, at a dose of 3 MU, given by subcutaneous injection daily for five days (days 3-7).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events
Time Frame: from the day of the leukapheresis up to 30 days after the last dose
|
Incidence, type and severity of adverse events occurred during treatment will be reported and graded according to NCI CTCAE 5.0 criteria
|
from the day of the leukapheresis up to 30 days after the last dose
|
Immunological efficacy
Time Frame: at 4 months, after at least 3 vaccinations
|
immunological efficacy will be assessed as a proportion of tumor-specific circulating immune effectors determined by IFNgamma ELISPOT
|
at 4 months, after at least 3 vaccinations
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: Up to 7 years
|
OS is the time from registration to the time of death from any cause.
Subjects who are alive at the time of the final analysis or who have become lost to follow-up will be censored at their last known alive date.
|
Up to 7 years
|
Relapse Free Survival (RFS)
Time Frame: Up to 7 years
|
RFS is the time from registration to the first date of documented progression (or death for any causes).
Subject without progression will be censored at their last tumor assessment date.
|
Up to 7 years
|
Predictive role of Delayed-Type Hypersensitivity (DTH) skin test
Time Frame: Up to 7 years
|
Evaluation of the predictive role of a positive DTH test after at least three vaccine administrations
|
Up to 7 years
|
Collaborators and Investigators
Investigators
- Study Chair: Laura Ridolfi, MD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neoplasms
- Sarcoma
- Head and Neck Neoplasms
- Neuroendocrine Tumors
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antineoplastic Agents
- Interleukin-2
Other Study ID Numbers
- IRST100.42
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on Autologous DC vaccine
-
Edward HirschowitzNational Cancer Institute (NCI)CompletedVaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung CancerLung CancerUnited States
-
Sharon RiddlerNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Rockefeller UniversityMemorial Sloan Kettering Cancer CenterCompleted
-
N.N. Petrov National Medical Research Center of...UnknownSarcoma | Neoplasms, Connective and Soft TissueRussian Federation
-
The Second Hospital of Shandong UniversityShandong Sunstem Biotechnology Co.,Ltd.Unknown
-
Affiliated Hospital to Academy of Military Medical...UnknownSmall- Cell Lung Cancer
-
Baylor College of MedicineCancer Cures for KidsRecruitingPancreatic Cancer | Pancreatic AdenocarcinomaUnited States
-
Affiliated Hospital to Academy of Military Medical...Unknown
-
Istituto Scientifico Romagnolo per lo Studio e...WithdrawnCarcinoma, Renal Cell | Secondary | VaccinationItaly
-
H. Lee Moffitt Cancer Center and Research InstituteJohns Hopkins All Children's HospitalWithdrawnNeoplasms, Nerve Tissue | Neuroblastoma